BVA-Guided Care Can Reduce Mortality Rate for Heart Failure Patients

Daxor Corporation is touting new study data validating the benefits of its BVA-100 blood test for heart failure patients. 

The study, “Heart Failure Outcomes with Volume-guided Management in an Over-65 Population” showed this cohort of patients experienced markedly better outcomes compared with controls for 30-day readmissions (12% vs. 27.0%, P< .001), 30-day mortality (2.3% vs. 11.8%, P< .001), and 365-day mortality (5.6% vs. 36.8%, P< .001) rates.
 
“This study shows the substantial benefit of BVA-guided care for Medicare patients with heart failure,” Chief Scientific Officer Jonathan Feldschuh stated. “Reducing the mortality rate by 81% on a 30-day basis and 85% on a one-year basis (from 36.8% to 5.6%) for one of the leading causes of death in the U.S. has been shown to be attainable with BVA in this 216 patient study. The study also showed a 56% lower rate of 30-day rehospitalization which points to a strong economic benefit for payers.”
 
“Understanding the impact of treatment decisions on outcomes for the over-65 population is of relevance to U.S. healthcare, as decisions made by the Centers for Medicare & Medicaid Services (CMS) regarding reimbursement, outcome-based incentives and penalties applied to health providers, and indication guidelines have enormous impact on how healthcare is provided,” said John E. Strobeck, M.D., PhD, the study’s principal investigator. 
 
Daxor Corporation develops blood volume measurement technology focused on blood volume testing innovation. The company’s BVA-100 (Blood Volume Analyzer) is marketed as the only diagnostic blood test cleared by the U.S. Food and Drug Administration to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. More than 60,000 tests have been performed at U.S. hospitals, enhancing performance metrics in a range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis.